Validation of a new prognostic model to predict short and medium-term survival in patients with liver cirrhosis.
Tomasz DziodzioRobert ÖllingerWenzel SchöningAntonia RothkäppelRadoslav NikolovAndrzej JuraszekPaul V RitschlMartin StockmannJohann PratschkeMaximilian JaraPublished in: BMC gastroenterology (2020)
The CreLiMAx risk score appears to be a competitive and valid tool for estimating not only short- but also medium-term survival of patients with end-stage liver disease. Particularly in patients with Child-Pugh Class B cirrhosis the new score showed a good ability to identify patients not at risk of death.